GSK, Partner Vir Join Race to Find COVID-19 Antibody Treatment GSK, Partner Vir Join Race to Find COVID-19 Antibody Treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news